Study of tumor necrosis factor-α-308 promoter polymorphism in psoriasis vulgaris

El-Farargy, Shawky M; Farag, Azza Gaber Antar; Azmy, Rania; Abdullah, Mona S.

doi:10.1097/01.ewx.0000445218.46201.6a

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study found that TNF-α serum levels in psoriatic patients were extremely significantly high (3.98 ± 0.65) and (6.85 ± 1.12) pg/ml, respectively (P = 0.001) [9].…”

Section: Discussionmentioning

confidence: 96%

Progranulin/Tumor Necrosis Factor-\(\alpha\) ratio in Psoriasis Vulgaris

Sheir¹,

Badr

Hodeib

et al. 2022

JAMMR

View full text Add to dashboard Cite

Background and Aim: In psoriasis, the proteins Tumor Necrosis Factor (TNF) and interleukin-6 (IL-6) are overexpressed and play important roles in the disease's progression. For treating psoriasis, biological drugs that target TNF signaling are quite successful. Embryogenesis, tissue repair, cancer, neuronal survival, host defense, and inflammation are all dependent on progranulin (PGRN). By competing with TNF binding to TNFR1/2, PGRN inhibits TNF-mediated signaling pathways and has anti-inflammatory properties in inflammatory arthritis models. The current research seeks to study the relationship between serum PGRN / TNF - \(\alpha\)and psoriasis vulgaris activity. Subjects & Methods: This study’s subjects were categorized into 2 groups: group 1 with 35 patients with psoriasis vulgaris, and group 2 of 30 healthy subjects with matched age and sex. Results: We discovered a significant increase in PGRN and TNF-\(\alpha\)in cases versus control. And we have found a significant decrease in PGRN/TNF-\(\alpha\)ratio in cases versus control. We also detected significant differences between the Psoriasis Area Severity Index (PASI) degree and the levels of PGRN and TNF-\(\alpha\), as well as the PGRN/TNF-\(\alpha\)ratio. We discovered a negative significant correlation between PASI and PGRN/TNF-\(\alpha\)ratio. Conclusion: Atsttrin exhibited potent anti-inflammatory properties due to its three modified granulin motifs and their associated linker regions. In the treatment of rheumatoid arthritis and contact dermatitis, PGRN and its derivative Atsttrin may be a potential therapeutic drug.

show abstract

“…Another study found that TNF-α serum levels in psoriatic patients were extremely significantly high (3.98 ± 0.65) and (6.85 ± 1.12) pg/ml, respectively (P = 0.001) [9].…”

Section: Discussionmentioning

confidence: 96%

Progranulin/Tumor Necrosis Factor-\(\alpha\) ratio in Psoriasis Vulgaris

Sheir¹,

Badr

Hodeib

et al. 2022

JAMMR

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a common chronic‐relapsing, immune‐mediated disease involving skin and joints of genetically predisposed individuals . Even though, psoriasis etiology remains unknown, it is believed to be multifactorial with numerous key components including genetic susceptibility, environmental triggers in combination with skin barrier disruption, and immune dysfunction . These triggers activate dendritic cells that migrate to the skin‐draining lymphatics and activate antigen‐specific T cells to differentiate into effector T cells.…”

Section: Introductionmentioning

confidence: 99%

Progranulin and beta‐catenin in psoriasis: An immunohistochemical study

Farag

Shoaib

Samaka

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background/Objectives Progranulin (PGRN) is a secreted glycoprotein that was investigated in many skin diseases. It plays an important role in inflammatory response and autophagy which could be mediated through Wnt/β‐catenin pathway. However, the role of PGRN in pathogenesis of psoriasis has not been clearly well‐known. Therefore, we aimed by this study to investigate the possible role of progranulin in psoriasis pathogenesis through evaluation of its immunohistochemical expression in lesional and perilesional skin of psoriasis patients and to investigate if its hypothesized role is mediated through β‐catenin or not. Methods This case‐control study was carried out on 37 patients presented with variable degrees of psoriasis vulgaris severity vs 37 age and sex‐matched apparently healthy volunteers. Psoriasis area and severity index (PASI) score was used to evaluate the severity of psoriasis. From all cases (lesional and perilesional) and controls, skin biopsies were taken for histopathological and immunohistochemical evaluation of PGRN and β‐catenin. Results There was a significant stepwise upregulation of PGRN from controls (76.2 ± 11.9) to perilesional (178.7 ± 11.8) and lesional (242.7 ± 12.7) psoriatic skin (P < 0.001). PGRN expression was significantly correlated with psoriasis severity (r = 0.61; P < 0.001). β‐catenin showed a significant stepwise downregulation from control (210.0 ± 19.3) to perilesional (131.4 ± 9.2) and lesional (97.3 ± 11.5) psoriatic skin(P < 0.001). There was a significant negative correlation between PGRN and β‐catenin expression in psoriatic skin (P < 0.001). Conclusions Progranulin has a pro‐inflammatory effect in the psoriasis pathogenesis, which could be mediated through a decreasing β‐catenin expression in psoriasis. PGRN may be used as a target for immunotherapy in psoriasis management program.

show abstract